Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market

CEO Dennis Carcillo is a former National Hockey League “tough guy”. Over the course of his NHL playing career, Carcillo sustained several TBIs. As the cumulative toll from these injuries increased, Carcillo sought treatment.

Nothing worked.

Said Carcillo, “I thought I was hopeless because I tried everything. I read every paper. And I couldn’t help myself. That's when suicidal ideation crept in for the first time in my life. It got really scary.”

After his first effort at self-medicating with psilocybin:

“I felt a little bit of joy come back in my life. I wanted to grab my phone and call my wife right away and reconnect with my kids. I felt like the brain fog and fatigue was starting to lift. It just got better progressively as the days went on.”

After six months, Carcillo was told his brain scans showed noticeable improvement.

Today, as Wesana’s CEO, Carcillo wants to bring psilocybin-based relief to other TBI sufferers, but via licensed-and-approved drugs, and alongside formal psychotherapy.

(Click on image to enlarge)

Somewhat more advanced is Neuronasal Llc. Part of the atai research platform, Neuronasal’s research is also at the pre-clinical stage and is focused on mild Traumatic Brain Injury (mTBI).

Its lead drug is an N-acetylcysteine derivative and it has already been approved by the FDA as an Investigational New Drug (IND). Neuronasal’s R&D is based around a unique nose-to-brain delivery system.

Revive Therapeutics (CAN: RVV / US: RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D.

Lobe Sciences (CAN: LOBE / US: GTSIF) is another public company that has announced plans for formal clinical research on mild Traumatic Brain Injury. Also at the pre-clinical stage, Lobe is looking at both psychedelic- and NAC-based options for its research.

Early industry leader, Champignon Brands (CAN: SHRM / US: SHRMF) is also involved in TBI-related R&D that is at the preclinical stage. Still, under a CTO from the B.C. Securities Commission, Champignon’s operations continue to be impeded by its regulatory issues.

View single page >> |

Disclaimer: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
James Hunter 1 month ago Member's comment

Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."

James Hunter 1 month ago Member's comment

Bright future for psychedelics TBI R&D

With a half-dozen companies in the psychedelics industry already with announced plans for TBI-related research, some investors may see this R&D niche as crowded.

But with a huge treatment population and an equally huge treatment market to target (estimated to reach $182 billion by 2027), there are more than enough revenue dollars on the table for second- and third-place finishers in this derby to be well-rewarded by the market.